THALES
16.6.2020 08:02:09 CEST | Business Wire | Press release
The Samsung Galaxy S20 will be the first and only device on the market to feature Thales’ technological breakthrough1 - the world’s first smartphones featuring a secure single-chip solution to support both mobile connectivity and trusted contactless services. The use of this innovative connected eSE offers new possibilities for the next generation of consumer devices that pack a wide range of NFC 2 services including secure payments or transport ticketing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005300/en/
Growing rapidly in popularity, the eSIM enables effortless remote access to connectivity. Users can manage their mobile subscriptions without having to fit or replace SIM cards. Galaxy S20 users will be able to enjoy seamless mobile connectivity and contactless applications such as payments, transit ticketing and digital ID (including mobile passports and mobile driver licenses ) in compliance with the relevant industrial specifications (GSMA, payment and transit organisations). This all-in-one connected eSE also saves further valuable space in smartphones, smartwatches and tablets.
“At Samsung, we’re constantly striving to provide consumers with the most advanced technology that will enable new and exciting experiences that people can trust. We’re excited to partner with Thales to offer Galaxy S20 users a unique solution that will offer seamless connectivity and robust security. The Galaxy S20 boasts the highest level of data protection and encryption with Common Criteria Evaluation Assurance Level (CC EAL) 6+ certification. This demands greater component miniaturization while maintaining an advanced level of security, ably demonstrated by Thales’ single-chip integration of eSE and eSIM.”
Daniel Ahn, Senior Vice President and Head of Mobile Security Team, Mobile Communications Business, Samsung Electronics.
“Continuing eSIM integration by the world’s leading smartphone brands, alongside the launch of next-generation devices such as the Samsung S20 range, will move eSIM-compliant smartphone shipments from 143 million in 2019 to in excess of 509 million in 2024.”
Phil Sealy, Research Director, Digital Security research, ABI Research
“This partnership reflects Samsung’s deep trust in Thales, a world leader in eSIM technology and related subscription management services
. Cutting the number of separate components needed within such devices also streamlines inventory and manufacturing processes, boosting productivity and profitability. Thales is uniquely placed in terms of its relationships with key service providers for contactless applications, including banks
, mobile operators
, automotive makers
, transport providers and governments
.”
Emmanuel Unguran, Thales Senior Vice President for Mobile Connectivity Solutions
Related resource: What is an eSIM : 6 illustrated answers infographic
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Market page
Download HD photos
1
Availability may vary across markets and models.
2
NFC (Near Field Communication) is a standardized wireless communication technology allowing for data exchange between devices that are a few centimetres distant (up to 5 cm). NFC embedded secure element shipments are expected to reach 473 million units among mobile devices by 2024.
Source: ABI Research – March 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005300/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom